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Objective: To compare treatment with stimulant medications to nonstimulant medications and/or 
nonpharmacologic interventions on professional and interpersonal functioning in adults with 
attention-deficit/hyperactivity disorder (ADHD). 
Method: Systematic literature review of five databases; 22 articles containing 323 studies 
(N=21,370) were included in this review.  
Results: Psychostimulants remain the most studied treatment for adults with ADHD and boast 
larger effect sizes than nonstimulant and nonpharmacologic therapy. Among nonpharmacologic 
therapy, cognitive behavior therapy (CBT) has proven most successful in randomized controlled 
trials. Effects of CBT are enhanced when combined with pharmacotherapy. 
Conclusions: Psychostimulants continue to be the most frequently prescribed treatment for 
adults with ADHD. Nonstimulant medications and nonpharmacotherapy remain used as an 
adjunct or alternative to psychostimulant therapy, but show promise in producing long-term 
improvements in professional and interpersonal functioning in adults with ADHD. 
Keywords: ADHD, adult, stimulants, stimulant medication, nonstimulant medication, 











Treatment of Adults with Attention-Deficit/Hyperactivity Disorder: 
A Systematic Literature Review 
Attention-deficit/hyperactivity disorder (ADHD) is a condition that initially presents in 
childhood, affecting 5-7.2% of children (APA, 2013; Alyagon et al., 2020). While it was 
originally thought that the disorder would be outgrown, it is now known that up to 65% of 
children will continue to experience difficulty with attention and executive functioning into 
adulthood (Aoshima-Kilroy et al., 2017; Baird et al., 2019; De Crescenzo et al., 2017; Geffen & 
Forster, 2018; Goto et al., 2013; Lenzi et al., 2017; Schwarz, 2016; Smith et al., 2020). The 
condition affects more than 2.5% of adults in the United States and over 4% of adults worldwide 
(APA, 2013; Alyagon et al., 2020; Baird et al., 2019; Boland et al., 2020). Adults with ADHD 
may experience increased difficulty with relationships, academics, and maintenance of 
employment when compared to their peers (Boland et al., 2020; Corbisiero et al., 2018; Geffen et 
al., 2018; Goto et al., 2017). Comorbid substance use, anxiety, and mood disorders are present in 
up to 70% of adults with ADHD. Untreated adults with ADHD experience increased rates of 
accidental injury and premature mortality (Aoshima-Kilroy et al., 2017; APA, 2013; Boland et 
al., 2020; Corbisiero et al., 2018; De Crescenzo et al., 2017; Geffen et al., 2018; Lenzi et al., 
2017).   
The DSM-V (2013) defines ADHD as a neurodevelopmental disorder characterized by a 
“persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning 
or development”. It is characterized by the presence of at least one of the following criteria: 
Inattention or hyperactivity and impulsivity. Inattention is defined as having five or more of the 
following symptoms: Careless mistakes, difficulty sustaining attention, mind wandering, failure 




mental effort, often losing necessary objects, is easily distracted, and/or is often forgetful (APA, 
2013). To meet the criteria for hyperactivity and impulsivity, at least five of the following 
symptoms must be present: Frequent fidgeting, inability to remain seated, restlessness, inability 
to engage in quiet activities, is often “on the go” and unable to be still for prolonged periods of 
time, talks excessively, engages in interrupting behaviors, and/or has difficulty waiting their turn 
patiently (APA, 2013). The symptoms required to meet the criteria for inattention, hyperactivity, 
or impulsivity make up the core symptoms of ADHD.   
ADHD may be predominantly inattentive type, hyperactive/impulsive type, or may be a 
combined presentation of the two. The symptoms must be present prior to age 12, in two or more 
settings (home, school, work, extracurriculars, or leisure), and pervasively interfere with 
functioning (APA, 2013). While the condition may co-occur with other mental disorders, the  
symptoms should not occur exclusively with flare-ups of these disorders (APA, 2013). Adults 
with ADHD may present differently than children and complain of inattention, restlessness, and 
emotional dysregulation rather than disruptive behaviors; they also tend to be more talkative than 
their peers (Baird et al., 2019).   
Standardized Tools 
 The standardized tools used to measure outcomes are highlighted in Table 4 of the 
appendix. The most common tools used were the Adult ADHD Self-Report Scale Symptoms 
Checklist (ASRS), Conners’ scales (both self- and observer-rated), Barkley scales, the 
Behavioural Rating Inventory for Executive Functioning (BRIEF-A), Wender scales, and 
Clinical Global Impressions (CGI) scales. Occupational functioning was measured using 
Endicott Work Productivity Scale (EWPS) and the Canadian Occupation Performance Measure 




life, self-esteem, and self-efficacy. Standardized tools to measure comorbid conditions were used 
to determine levels of anxiety, depression, and suicidality, though these conditions were not 
studied in this review.   
Pharmacologic Interventions 
Psychostimulant Pharmacotherapy 
 Psychostimulant medications work by blocking reuptake of dopamine and 
norepinephrine, thus increasing synaptic concentration of these neurotransmitters (Aoshima-
Kilroy et al., 2017). Use of these medications are considered the first-line treatment for adults 
with ADHD (Baird et al., 2019). Formulations may be immediate, intermediate, or long-acting 
and should be tailored to meet the individual’s needs (De Crescenzo et al., 2017). Common side 
effects of these medications include anxiety, gastrointestinal upset, appetite suppression, 
headache, sleep disturbances, fatigue, and blunted affect (Aoshima-Kilroy et al., 2017; Baird et 
al., 2019). Because these medications promote vasoconstriction, they can increase blood pressure 
and may raise the risk of cardiovascular events including myocardial infarction (Aoshima-Kilroy 
et al., 2017). Rarely, these medications may instigate seizure, psychosis, suicidality, priapism, 
and hepatotoxicity (Aoshima-Kilroy et al., 2017). Caution should be exercised when prescribing 
these medications for persons who experience hyperthyroidism, glaucoma, epilepsy, or severe 
anxiety disorder. They should not be used within two weeks of taking an MAOI or with those 
who experience cardiomyopathy, abnormal QT interval (prolonged or shortened), Brugada 
syndrome, Wolff-Parkinson-White syndrome, anorexia, psychosis, or Marfan syndrome 
(Aoshima-Kilroy et al., 2017). Because they are classified as a Schedule II drug with high 
potential for misuse and diversion by the Food and Drug Administration, prescribers must take 




Psychostimulant medications have been used in pregnancy for women with moderate to 
severe symptoms. However, placental perfusion may be impacted by the vasoconstrictive actions 
of psychostimulant medications and their use is associated with an increased risk for pre-
eclampsia (1.3 fold increase when taken in the first trimester) and pre-term birth (Cohen et al., 
2017). Benefits of the medication must be weighed against the risks of not treating women with 
severe ADHD as untreated women may experience increased anxiety and aggression that may 
interfere with self-care during pregnancy (Cohen et al., 2017).   
Nonstimulant Pharmacotherapy 
Atomoxetine. Atomoxetine, a noradrenaline reuptake inhibitor, works by promoting 
neurotransmitters noradrenaline and dopamine in the prefrontal cortex thus improving attention 
(Aoshima-Kilroy et al., 2017; Geffen et al., 2018). Insomnia, sedation, dizziness, gastrointestinal 
dysfunction, sexual dysfunction, increased blood pressure, and anticholinergic effects (dizziness, 
dry mouth, urinary retention, and increased heart rate) are common side effects (Aoshima-Kilroy 
et al., 2017; AthenaHealth, 2020). Atomoxetine may cause liver damage and regular monitoring 
of liver function tests is necessary (Aoshima-Kilroy et al., 2017; AthenaHealth, 2020). 
Bupropion. Bupropion is an aminoketone antidepressant. Its therapeutic effect is derived 
from its action of inhibiting reuptake of dopamine and noradrenaline (AthenaHealth, 2020; 
Verbeeck et al., 2017). Bupropion is structurally similar to psychostimulants, which translates to 
a similar, but less robust, action without the high risk of misuse and diversion that 
psychostimulants boast (Verbeeck et al., 2017). Headache, nausea, dry mouth, and insomnia are 
common side effects; additionally, bupropion lowers the seizure threshold, thus increasing 




the nearly 19% of adults with ADHD who experience comorbid major depression (CHADD, 
2019).  
Desipramine. Desipramine, a tricyclic antidepressant, inhibits norepinephrine and 
serotonin reuptake (AthenaHealth, 2020). It may be useful for adults who experience both major 
depressive disorder and ADHD. Desipramine has the potential for many adverse effects, the 
most common being drowsiness, anticholinergic effects (dry mouth, constipation, urinary 
retention), dizziness, palpitations, tachycardia, and gastrointestinal distress; it may also increase 
anxiety and agitation and cause restlessness and insomnia (AthenaHealth, 2020). Serious adverse 
effects include changes in blood pressure (hyper- or hypotension), cardiac arrhythmias, QT 
prolongation, torsades de pointes, and AV block. It may cause myocardial infarction, 
cerebrovascular accident, extrapyramidal symptoms and tardive dyskinesia, serotonin syndrome, 
psychosis, suicidality, hepatitis, and angioedema (AthenaHealth, 2020). Unlike psychostimulant 
medications, desipramine cannot be stopped abruptly. While taking the medication, providers 
should monitor therapeutic drug levels, suicidality, and behavior changes. Desipramine should be 
used with caution for anyone with a history of cardiovascular disease, electrolyte abnormalities, 
QT prolongation, torsades de point, arrhythmias, angle-closure glaucoma, seizure disorder, 
thyroid disease, diabetes mellitus, psychosis, Parkinson’s disease, or alcohol abuse 
(AthenaHealth, 2020). 
Nonpharmacologic Interventions 
Nonpharmacologic therapy may be used as an alternative to pharmacotherapy by persons 
who are unable to tolerate, whose symptoms are inadequately controlled by, or who do not wish 
to take medication. While there are many nonpharmacologic options for symptom control in 




in the form of cognitive behavior therapy (CBT); CBT has been the most studied. CBT was 
developed in the 1960’s; however, only recently has this therapy been integrated into ADHD 
treatment (CHADD, 2021). CBT addresses ADHD symptoms by teaching organizational, 
executive functioning, and emotional regulation skills (CHADD, 2021). Mindfulness meditation 
has been used to improve emotional regulation (Bachman et al., 2016; De Crescenzo et al., 
2017). Non-invasive brain stimulation has been FDA approved to treat depression and 
obsessive/compulsive disorder and has been postulated to improve ADHD symptoms (Alyagon 
et al., 2020).   
While psychostimulants have been recommended by guidelines as the first-line therapy 
for ADHD in adults, these medications carry the risk of adverse effects. Up to 50% of adults 
taking psychostimulant medication discontinue their use within three years (Smith et al., 2020; 
Verbeeck et al., 2017). For those who do continue psychostimulant therapy, many are left with 
incomplete symptom coverage, unwanted side-effects, and difficulty functioning during times 
when medication is not taken (Cherkasova et al., 2016). The purpose of this literature review is 
to compare treatment using psychostimulant medications to nonstimulant medications and/or 
nonpharmacologic interventions on professional and interpersonal functioning in adults with 
attention-deficit/hyperactivity disorder (ADHD).   
Method 
Databases 
A literature search was performed using five electronic databases, including Academic 
Search Premier, CINAHL, PubMed, ProQuest: Nursing and Allied Health Database, and 




neuropsychiatric-related articles. Descriptions of each database can be found in Table 1 of the 
Appendix. 
Study Selection and Search Strategies 
The protocol for critically appraising evidence outlined by Melnyk and Overholt (2019) 
guided this systematic review of the literature. The search terms are outlined in Table 2 of the 
Appendix. The search was limited to scholarly, peer-reviewed articles in the English language. 
Studies published between January 2015 and January 2021 were eligible for consideration in 
order to provide the most recent research available. Articles considered for inclusion must have 
1) included pharmacologic and/or nonpharmacologic therapy for adults with ADHD and 2) 
evaluated observed and/or perceived effects to symptoms and professional and/or interpersonal 
functioning using standardized tools. Exclusion criteria included studies that involved children or 
adolescents, and those that investigated ADHD with comorbid psychiatric conditions, substance 
abuse, or pregnancy. Articles that were not available in full text were also excluded.  
As shown in the Figure 1, a search of the included databases resulted in 563 articles, 
which were screened at the abstract level and reduced to 43 articles. Those remaining articles 
were read in their entirety and 21 were excluded according to the criteria noted above with 
detailed reasons outlined in Table 3 of the Appendix. Twenty-two articles met final inclusion 
criteria for this review. Reference Table 4 for details regarding each study that was included.   
The studies contained data from around the world. Of the 22 articles, five were conducted 
in North American, seven were from Europe, two were from the Middle East, and one study was 
completed in Asia. The remaining articles either did not specify the country the study took place 




Close observation was given to study design, intervention, and primary and secondary 
outcomes. Of the 22 studies included, 21 were quantitative. One qualitative study was included 
to provide insight on what drives adults with ADHD to choose and maintain treatment. Due to 
the small size of this qualitative study, caution should be used generalizing the data to larger 
populations. Risk of inherent bias was present in many of the studies due to concealment of 
randomization process. An additional limitation to this review was the volume of included 
studies. Multiple meta-analyses were included in this review and some of the studies were 
duplicated within these analyses. Enacting more strict search parameters or limiting meta-
analyses would have yielded a more manageable dataset. 
Figure 1 













North America 5 
Europe 7 
Middle East 2 
Asia 1 





Total Studies: 342  
Sample Size N=21,370 
Stimulant Therapy N=9,944 
Nonstimulant Therapy N=5,500 
Non-pharmacotherapy  N=164 
Multi-Modal N=92 
 
Effects of Interventions  
Stimulant Medication  
Psychostimulant therapy is the most studied therapy for adults with ADHD. Their use is 
associated with improved core symptom control and increased attention (Fuermaier et al., 2016). 




productivity, and emotional dysregulation leading to improved quality of life when compared to 
other psychostimulants, nonstimulant medications, and placebo (Goodman et al., 2017; Lenzi et 
al., 2018). These improvements were shown through both provider- and self-rated standardized 
tools. While Baird et al. (2019) found that amphetamine use was not effective in improving 
global functioning or reducing co-existing anxiety and/or depression symptoms, a meta-analysis 
by Boland et al. (2020) discovered the opposite – psychostimulant use showed protective effects 
on mood disorders (p<0.001) and risk-behaviors with significant improvements to overall 
functioning compared to no medication (p<0.001). A meta-analysis by Elliot et al. (2020) 
revealed that use an any ADHD pharmacotherapy (psychostimulant or nonstimulant 
medications) was associated with a statistically significant improvement in executive functioning 
(95% CI [-7.15, -4.29]) with low risk of harms (95% CI [0.67, 2.18]). While psychostimulants 
boast larger effects than nonstimulant medications or nonpharmacologic therapy (p<0.00001), 
their use is also associated with more frequent adverse events (p=0.006) (Cunill et al., 2016).  
Nonstimulant Medication 
While nonstimulant medications are more efficacious than placebo at reducing core 
ADHD symptoms, they are not as effective as psychostimulant medications in randomized 
controlled trials (De Crescenzo et al., 2017). Atomoxetine is the most studied among the 
nonstimulant medications. It has been shown to reduce core ADHD symptoms and improve 
executive functioning with fewer adverse effects than psychostimulant medications (p<0.001) 
(Goto et al., 2017). Those receiving atomoxetine also experienced improvements in quality of 
life (p<0.001), life outlook (p<0.05), productivity (p<0.001), and relationships (p=0.007) (Goto 
et al., 2017). According to a study by Verbeeck et al. (2017), bupropion proved superior to 




tolerability to placebo (95% CI [0.35, 4.10]), though the evidence was of low quality. Bupropion 
and desipramine may be a useful treatment when considering pharmacotherapy for adults who 
have co-existing mood disorder as their primary use is for the treatment of depression.  
Nonpharmacologic Therapy   
 Multiple nonpharmacologic therapies were studied in this literature review. Various 
forms of psychotherapy have been shown to be beneficial in reducing core ADHD symptoms for 
individuals with mild ADHD or those with incomplete symptom management despite 
pharmacotherapy (Groß et al., 2019). CBT has the most support as a viable treatment for adults 
with ADHD, however results are not as rapid as pharmacotherapy and effect sizes remain much 
smaller than treatment with psychostimulants alone (Smith et al., 2020). And while it has been 
shown to be effective, there are few studies that compare CBT without the addition of 
pharmacotherapy (Groß et al., 2019). When used in addition to pharmacotherapy, CBT has been 
shown to significantly reduce core ADHD symptoms and improve both occupational and social 
functioning when compared to standard treatment with pharmacotherapy alone (Dittner et al., 
2018; Groß et al., 2019). The medium-to-large effects of CBT are apparent regardless of whether 
or not pharmacotherapy is used (Knouse et al., 2017). Improved perceived anxiety, depression, 
and distress are secondary benefits of CBT in adults with ADHD (Dittner et al., 2018). 
Additional secondary benefits include improved time-management, organization, and planning 
skills, as well as increased knowledge and motivation for self-care (Smith et al., 2020). A further 
finding is continued statistically significant effects up to 18 months after treatment had ended 
when compared to usual care (Groß et al., 2019). Conversely, Corbisiero et al. (2018) found that 
the addition of CBT to stimulant pharmacotherapy was no more effective than standard clinical 




trained clinicians; this finding was, however, an outlier compared to the majority of the research 
described above.   
 Mindfulness meditation and mindfulness-based CBT were shown to significantly 
improve self-regulation, attention, and emotional control (Bachman et al., 2016; De Crescenzo et 
al., 2017; Janssen et al., 2018). When combined with pharmacotherapy, mindfulness-based CBT 
significantly reduced perceived and clinician-rated core ADHD symptoms with effects lasting 
through six months of follow-up (Janssen et al., 2019). While immediate effects on executive 
functioning were not observed with mindfulness-based CBT, this domain was improved at the 
six-month follow-up (Janssen et al., 2019). 
 Interventions targeting executive functioning skills such as establishing a routine, 
organization, and time management was shown to improve outcomes in women with ADHD 
(Gutman et al., 2020). Additional interventions that have been shown to improve executive 
functioning include stress management and environmental control by reducing distractions 
(Gutman et al., 2020). Prefrontal brain stimulation, similar to what has been used for mood 
disorders, has shown some promise in one small study. However, the treatment may cause 
physical discomfort and the long-term effects remain unknown (Alyagon et al., 2020). Other 
nonpharmacologic approaches, such as hypnotherapy and neurofeedback were not shown to be 
effective when compared to sham therapy (Smith et al., 2020).   
Gaps in Literature 
Multi-modal therapy is recommended for adults with ADHD. However, there is a paucity 
of studies that evaluate the long-term outcomes of multimodal therapy on symptom control and 
overall functioning. Additionally, little information exists on barriers to psychotherapy uptake 





Current guidelines recommend long-acting psychostimulant medication 
(methylphenidate) as first-line treatment for adults with ADHD who have significant impairment 
in at least one domain (ADHD Institute, 2019; National Institute for Health and Care Excellence 
(NICE), 2019). Use of such medications may result in more than 30% improvements in core 
symptom reduction (Grade B recommendation) (Baird et al., 2019). Nonstimulant medications 
remain second-line treatment for adults with ADHD, and may be used in place of or as an 
adjuvant to psychostimulant medications. Multimodal therapy, including psychotherapy, is also 
recommended, though not widely utilized (ADHD Institute, 2019; Geffen et al., 2018; Groß et 
al., 2019; Lenzi et al., 2017; NICE, 2019). The risks and benefits of ADHD treatment in adults 
should be carefully considered and the decision on how to treat the symptoms should occur 
through shared decision making (Boland et al., 2020; Druedahl & Sporrong, 2018; Elliot et al., 
2020; Groß et al., 2019; Verbeeck et al., 2017).   
Pharmacotherapy has proven both safe and efficacious through numerous randomized 
controlled trials. Both memory and executive function, as well as emotional dysregulation, may 
be improved, though not normalized, using psychostimulant medications (Fuermaier et al., 2016; 
Lenzi et al., 2018). Unfortunately, benefits cease when the medication is discontinued or a dose 
is missed, and effects may be reduced over time. The addition of psychotherapy, specifically 
CBT, may be a means of bridging this gap and providing skills to improve long-term executive 
functioning which leads to improved social, occupational, and global functioning (Fuermaier et 
al., 2016; Janssen et al., 2019). While studies highlight that psychotherapy is less efficacious 
than pharmacotherapy, these options for treatment should be shared for all those who cannot 




for enhanced core symptom control (Cherkasova et al., 2016; Dittner et al., 2018; Groß et al., 
2019; Knouse et al., 2017). Discontinuation rates of psychostimulant therapy may be upwards of 
50% for reasons ranging from feelings of not being oneself and unsatisfactory symptom control 
to bothersome adverse effects (Druedahl et al., 2018; Verbeeck et al., 2017). Discontinuation 
rates may be mitigated with the addition of psychotherapy as pharmacotherapy provides 
immediate relief while individuals learn skills to cope with their ADHD (Alyagon, 2020; Cunill 
et al., 2016). It is worth noting that one study by Corbisiero et al. (2018) did not show CBT to be 
any more efficacious than standard clinical management when used in addition to 
pharmacotherapy. This study’s findings, however, were contrary to the remaining studies in this 
review. It should be noted that there were obvious limitations of this study including small 
sample (N=43) and uneven distribution of comorbid conditions between the control and 
intervention groups.  
In fact, Druedahl et al. (2018) found that many adults desired nonpharmacologic 
treatment for their ADHD but felt that they lacked knowledge about their options. Despite 
scientific studies boasting the effectiveness of therapies such as CBT, mindfulness, or skills 
training and recommendations for multimodal therapy, nonpharmacologic options remain a 
largely underutilized treatment for adults with ADHD in the United States. The key is to offer 
transparency in the course of treatment; while medications often provide immediate results, the 
effects of nonpharmacologic therapeutic options are more gradual, yet also longer lasting (De 
Crescenzo et al., 2017). Additionally, psychotherapy may be substantially costlier than 





While this review of literature was useful in uncovering the continued needs for research 
on nonpharmacologic and multimodal therapy in adults with ADHD, it did not address how to 
approach treatment of ADHD in adults with co-morbid substance use disorder. Substance use 
disorder has been shown to increase the risk of stimulant misuse (De Crescenzo et al., 2017).  
Implications for Future Practice 
Recommendations for Clinical Practice 
Primary care nurse practitioners and other medical providers should address biases 
related to diagnosis of adult ADHD and treatment with psychostimulant medications. 
Additionally, providers should increase their knowledge of nonpharmacologic therapies to use in 
addition to pharmacotherapy to optimize symptom management and professional and 
interpersonal functioning.  
Recommendations for Research   
Further research is needed on the long-term outcomes of treatment with psychostimulants 
compared with psychotherapy. Is CBT not well-utilized due to lack of knowledge on its efficacy 
or due to lack of providers who practice this form of therapy? Further research is warranted to 
explore barriers to CBT in adults with ADHD.  
Recommendations for Health Policy 
Currently, there is a scarcity of professionals trained to implement CBT for those 
diagnosed with ADHD. Increasing provider training in CBT, coping skills, and executive 






Psychostimulants remain the first-line treatment option for adults with ADHD, with 
nonstimulant medications and nonpharmacologic options considered second-line treatments that 
should be used in addition to psychostimulants or for those who are unable to tolerate 
psychostimulants. Nonpharmacologic options may also be considered as first-line treatment for 
individuals who express concern over a desire to not become reliant on medications. Regardless 
of the therapeutic option chosen, the patient’s individual concerns and life situation should be 
considered and the choice should be made through shared decision making after risks and 
benefits of all options have been discussed.  
In the absence of referral for psychotherapy, primary care nurse practitioners caring for 
adults with ADHD may provide counseling on nonpharmacologic interventions to manage their 
symptoms to enhance pharmacotherapy. Education on environmental management, such as 
establishing routines, working in a quiet, clutter-free setting, and minimizing distractions, 
coupled with stress-management techniques may be used to complement pharmacotherapy. 
Ensuring that primary care providers managing adults with ADHD are following the most 
current evidence and prescribing multimodal therapy is paramount in arming adults with ADHD 
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Table 1 
Database Search Description 
Database (or Search Engine) 
 
Restrictions Added to Search 
 
Dates Included in Database General Subjects Covered by 
Database 
1. Academic Search Premier Full Text; Peer Reviewed; English 
Language; Research Article 
2015-2020 Provides citations and abstracts to articles, as 
well as full text of articles from over 4,600 
publications, covering almost every academic 
subject. 
2. CINAHL  Full text; Peer Reviewed; English 
Language; Research Article 
2015-2020 Provides full text access to e-books about 
nursing and 29 core nursing journals. Also 
provides citations and abstracts to articles, 
books, dissertations, proceedings, and other 
materials about all aspects of nursing and 
allied health, including cardiopulmonary 
technology, emergency service, health 
education, medical/laboratory, medical 
assistant, medical records, occupational 
therapy, physical therapy, physician 
assistant, radiologic technology, social 
service/health care, and more. 
3. PubMed Full text; Peer Reviewed; English 
Language; Research Article 
2015-2020 Provides citations, abstracts, and selected full 
text to articles about "medicine, nursing, 
dentistry, veterinary medicine, the health care 
system, and the preclinical sciences." 
4. ProQuest: Nursing and Allied Health 
Database 
Full Text; Peer Reviewed; English 
Language; Research Article 
2015-2020 Provides citations, abstracts, and selected full 
text to articles about all aspects of nursing 
and allied health. 
5. PsycArticles Full Text; Peer Reviewed; English 
Language; Research Article 
2015-2020 Provides full-text articles from journals 
published by the American Psychological 
Association, the APA Educational Publishing 
Foundation, the Canadian Psychological 
Association, and Hogrefe & Huber. The 
database includes all material from the print 
journals with the exception of advertisements 
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Date of 
Search 
Key Words Results in 
Academic Search 
Premier 
Results in CINHAL Results in PubMed Results in 
ProQuest: Nursing 




11/2/2020 “ADHD”, “adult” 39,790 515 1,772 4,952  
11/2/2020 “ADHD”, “adult”, “stimulants” 5,517 65 265 1,054  
11/2/2020 “ADHD” AND “adult” AND “stimulant medication” 
AND “nonstimulant medication” NOT “child, 
adolescent” 
44 0 8 (6) 4 (0)  
11/6/2020 “ADHD” AND “adult” AND “nonpharmacologic” 165 0 27 42  
11/6/2020 “ADHD” AND “adult” AND “nonpharmacologic” 
NOT “child” NOT “children” NOT “adolescent” 
11(0) 0 9 (7) 9 (1)  
11/18/2020 “ADHD”, “adult”     1,273 
11/18/2020 “ADHD”, “adults”, “stimulants”     187 
11/18/2020 “ADHD” AND “adult” AND “stimulant medication” 
AND “nonstimulant medication” NOT “child, 
adolescent” 
    0 
11/18/2020 “ADHD” AND “adult” AND “nonpharmacologic”      2 (0) 
11/18/2020 “ADHD” AND “adult” AND “nonpharmacologic” 
NOT “child” NOT “children” NOT “adolescent” 
    0 
11/18/2020 “ADHD” AND “adult” AND “pharmacologic” NOT 
“child” NOT “adolescent”  
    18 (0) 
11/19/2020 “ADHD” AND “adult” AND “methylphenidate” AND 
“cognitive behavior therapy” 
1,403 2 (1)   39 (3) 
11/19/2020 “ADHD” AND “adult” AND “methylphenidate” AND 
“cognitive behavior therapy” NOT “child” NOT 
“adolescent”  
85 (7)  4 (2)  39 (0) 
1/17/2021 “atomoxetine” AND “ADHD” AND “adult” NOT 
“child” NOT “adolescent” NOT “pediatric” 
97 (3) 6 (1) 19 (1) 198 (5) 13 (0) 
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Bachmann, K., Lam, A. P., & Philipsen, A. (2016). Mindfulness-based 
cognitive therapy and the adult ADHD brain: A neuropsychotherapeutic 
perspective. Frontiers in Psychiatry, 27(7), 117. 
https://doi.org/10.3389/fpsyt.2016.00117 
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Use of mindfulness as a treatment modality for ADHD; limitations, 
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Baird, D., & Hoffman, A. (2019). Use of amphetamines for attention-
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https://www.aafp.org/afp/2019/0901/p278.html  
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Biederman, J., DiSalvo, M., Woodworth, K. Y., Fried, R., Uchida, M., 
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operationalizing deficient emotional self-regulation in newly referred adults 
with ADHD: A receiver operator characteristic curve analysis. European 
Psychiatry, 63(1):e21. https://doi.org/10.1192/j.eurpsy.2019.11 
Excluded Focus of the article was on deficient emotional self-regulation 
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Boland, H., DiSalvo, M., Fried, R., Woodworth, K. Y., Wilens, T., Faraone, S. 
V., & Biederman, J. (2020). A literature review and meta-analysis on the 
effects of ADHD medications on functional outcomes. Journal of Psychiatric 
Research, 123, 21–30. https://doi.org/10.1016/j.jpsychires.2020.01.006 
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causality or effects of pharmacotherapy 
Cherkasova, F., French, L. R., Syer, C. A., Cousins, L., Galina, H., Kashani, 
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Included Comparison of group CBT alone versus combine with medication on 
ADHD symptoms and functional outcomes in adults 
Limitations: absence of blinded independent evaluations of treatment 
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Coogan, A. N., Schenk, M., Palm, D., Uzoni, A., Grube, J., Tsang, A. H., 
Kolbe, I., McGowan, N. M., Wandschneider, R., Colla, M., Oster, H., Thome, 
J., & Faltraco, F. (2019). Impact of adult attention deficit hyperactivity 
disorder and medication status on sleep/wake behavior and molecular circadian 
rhythms. Neuropsychopharmacology, 44(7), 1198-1206. 
https://doi.org/10.1038/s41386-019-0327-6 
Excluded Small study on the effects of ADHD and medications to treat the 
condition on sleep and circadian rhythms, did not evaluate the impact 
of medications on functional status 
Cohen, J. M., Hernández-Díaz, S., Bateman, B. T., Park, Y., Desai, R. J., Gray, 
K. J., Patorno, E., Mogun, H., & Huybrechts, K. F. (2017). Placental 
complications associated with psychostimulant use in pregnancy. Obstetrics 
and Gynecology, 130(6), 1192-1201. 
https://doi.org/10.1097/AOG.0000000000002362 
Excluded Exclude for literature review; pregnancy appears an outlier in the 
research and will omit from the review.  Consideration of mentioning 
the risks of stimulant use during pregnancy (pre-eclampsia, placental 
abruption, growth restriction, preterm birth) in introduction or 
discussion 
Corbisiero, S., Bitto, H., Newark, P., Mörstedt, B. A-, Elsässer, M., 
Kammermann, J. B-, Künne, S., Nyberg, E., Fallahpour, M. H-, & Stieglitz, R. 
D. (2018).  A comparison of cognitive-behavioral therapy and 
pharmacotherapy vs. pharmacotherapy alone in adults with attention-
deficit/hyperactivity disorder (ADHD) -- A randomized controlled trial. 
Frontiers in Psychiatry, 9(571). http://doi.org/10.3389/fpsyt.2018.00571 
Included Comparison of CBT with medication versus medication alone on 
ADHD symptoms and functional outcomes in adults 
Cunill, R., Castells, X., Tobias, A., & Capellà, D. (2016). Efficacy, safety and 
variability in pharmacotherapy for adults with attention deficit hyperactivity 
disorder: A meta-analysis and meta-regression in over 9000 
patients. Psychopharmacology, 233(2), 187-197. 
http://dx.doi.org.ezproxy.mnsu.edu/10.1007/s00213-015-4099-3 
Included Systematic review and meta-analysis of RCTs comparing 
pharmacologic treatments in adults with ADHD 
De Crescenzo, F., Cortese, S., Adamo, N., & Janiri, L. (2017). 
Pharmacological and non-pharmacological treatment of adults with ADHD: A 
meta-review. Evidence - Based Mental Health, 20(1), 4. 
http://dx.doi.org.ezproxy.mnsu.edu/10.1136/eb-2016-102415 
Included Systematic review of treatments for adults with ADHD including 
both pharmacologic and nonpharmacologic therapies 
Demiral, S. B., Tomasi, D., Wiers, C. E., Manza, P., Kojori, E. S-, 
Studentsova, Y., Wang, G., & Volkow, N. D. (2018). Methylphenidate’s 
effects on thalamic metabolism and functional connectivity in cannabis abusers 
and healthy controls. Neuropsychopharmacology, 44(8), 1389–1397. 
https://doi.org/10.1038/s41386-018-0287-2 
Excluded Did not meet inclusion criteria as participants experienced cannabis 
use disorder, not ADHD 
Dittner, H., Hodsoll, J., Rimes, K. A., Russell, A. J., & Chalder, T. (2018). 
Cognitive-behavioural therapy for adult attention-deficit hyperactivity 
disorder: A proof of concept randomised controlled trial. Acta Psychiatrica 
Scandinavica, 137(2), 125–137. https://doi.org/10.1111/acps.12836 
Included Randomized controlled trial comparing treatment as usual to 
treatment as usual plus cognitive behavior therapy 
Druedahl, L. C., & Sporrong, S. K. (2018) Managing complexity: Exploring 
decision making on medication by young adults with ADHD. Pharmacy 
(Basel), 6(2), 33. https://doi.org/10.3390/pharmacy6020033 
Included Qualitative study exploring experiences of young adults with ADHD 









Elliott, J., Johnston, A., Husereau, D., Kelly, S. E., Eagles, C., Charach, A., 
Hsieh, S., Bai, Z., Hossain, A., Skidmore, B., Tsakonas, E., Chojecki, D., 
Mamdani, M., & Wells, G. A. (2020). Pharmacologic treatment of attention 
deficit hyperactivity disorder in adults: A systematic review and network meta-
analysis. PloS One, 15(10), e0240584–e0240584. 
https://doi.org/10.1371/journal.pone.0240584 
Included Meta-analysis of pharmacologic treatments for adults with ADHD 
Fuermaier, A. B. M., Tucha, L., Koerts, J., Weisbrod, M., Lange, K. W., 
Aschenbrenner, S., & Tucha, O. (2017). Effects of methylphenidate on 
memory functions of adults with ADHD. Applied Neuropsychology: Adult, 
24(3), 199-121. https://doi.org/10.1080/23279095.2015.1124108 
Included Treatment with methylphenidate in adults with ADHD improves, but 
does not normalize, memory function. 
Geffen, J., & Forster, K. (2018). Treatment of adult ADHD: A clinical 
perspective. Therapeutic Advanced Psychopharmacology, 8(1), 25-32. 
https://doi.org/10.1177/2045125317734977 
Included Synthesis of information 
Clinical perspective of treatment options for adult individuals with 
ADHD.  Guideline for practice 
Goodman, D. W., Starr, H. L., Ma, Y. W., Rostain, A. L., Ascher ,S., & 
Armstrong, R. B. (2017).  Randomized, 6-week, placebo-controlled study of 
treatment for adult attention-deficit/hyperactivity disorder: Individualized 
dosing of osmotic-release oral system (OROS) methylphenidate with a goal of 
symptom remission. Journal of Clinical Psychiatry, 78(1), 105-114. 
https://doi.org/10.4088/JCP.15m10348 
Included Use of osmotic-release oral system (OROS) methylphenidate on 
symptom reduction in adults with ADHD 
Goto, T, Hirata, Y., Takita, Y., Trzepacz, P. T., Allen, A. J., Song, D., Gau, S. 
S., Ichikawa, H., Takahashi, M. (2017). Efficacy and Safety of Atomoxetine 
Hydrochloride in Asian Adults With ADHD. Journal of Attention Disorders, 
21(2), 100–109. https://doi.org/10.1177/1087054713510352 
Included RCT of safety and efficacy of atomoxetine in adults with ADHD. 
Limitations include exclusion of comorbid psychiatric conditions 
which authors note limits generalizability of results to many 
individuals experiencing ADHD.  Study used a flexible-dose design 
which made it challenging to determine safety and efficacy 
Groß, V., Lücke, C., Graf, E., Lam, A. P., Matthies, S., Borel, P., Sobanski, E., 
Rösler, M., Retz, W., Jacob, C., Colla, M., Huss, M., Jans, T., Kis, B., Hamid, 
M. A-, van Elst, L. T., & Philipsen, A. (2019). Effectiveness of psychotherapy 
in adult ADHD: What do patients think? Results of the COMPAS study. 
Journal of Attention Disorders, 23(9), 1047–1058. 
https://doi.org/10.1177/1087054717720718 
Included Study of patient perspectives on psychotherapy for adults with 
ADHD 
Gutman, S. A., Balasubramanian, S., Herzog, M., Kim, E., Swirnow, H., Retig, 
Y., & Wolff, S. (2020). Effectiveness of a tailored intervention for women 
with attention deficit hyperactivity disorder (ADHD) and ADHD symptoms: A 
randomized controlled study. American Journal of  Occupational Therapy, 
74(1), 1-11. https://doi.org/10.5014/ajot.2020.033316 
Included Randomized controlled study investigating reduced perceived stress 
and ADHD symptoms and enhanced perceived performance of and 
satisfaction with desired occupational roles and activities in a sample 
of women 
Limitation of small sample size, low statistical power; lack of formal 
diagnosis in 4 of the women 
Huang, F, Qian, Q., & Wang, Y. (2015). Cognitive behavioral therapy for 
adults with attention-deficit hyperactivity disorder: study protocol for a 









randomized controlled trial. Trials, 16(1), 161–161. 
https://doi.org/10.1186/s13063-015-0686-1 
Imagawa, H., Nagar, S. P., Montgomery, W., Nakamura, T., Sato, M., & 
Davis, K. L. (2018). Treatment patterns, health care resource utilization, and 
costs in Japanese adults with attention-deficit hyperactivity disorder treated 
with atomoxetine. Neuropsychiatric Disease Treatment,14, 611-621. 
https://doi.org/10.2147/NDT.S150261 
Excluded Retrospective analysis of insurance claims data revealing patterns of 
medication adherence, discontinuation, and use of other medications. 
Not relevant to clinical question 
Jain, R., & Katic, A. (2016). Current and investigational medication delivery 
systems for treating attention-deficit/hyperactivity disorder. Primary Care 
Companion for CNS disorders, 18(4). https://doi.or/10.4088/PCC.16r01979 
Excluded Full text not available 
Janssen, L., Kan, C. C., Carpentier, P. J., Sizoo, B., Hepark, S., Schellekens, 
M. P. J., Rogier, A., Donders, T., Buitelaar, J. K., & Speckens, E. M. (2019). 
Mindfulness-based cognitive therapy v. treatment as usual in adults with 
ADHD: A multicentre, single-blind, randomised controlled trial. Psychological 
Medicine, 49(1), 55–65. https://doi.org/10.1017/S0033291718000429 
Included An exploration of the utility of mindfulness-based therapy versus 
treatment as usual in adults with ADHD 
Joseph, A., Cloutier, M., Guérin, A., Nitulescu, R., & Sikirica, V. (2016). 
Treatment outcomes after methylphenidate in adults with attention-
deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or 
atomoxetine. Patient Preference Adherence, 10, 391-405. 
https://doi.org/10.2147/PPA.S98498 
Excluded Retroactive cohort study examined medication continuation rates 
among adults receiving pharmacotherapy for ADHD 
Karlstad, Ø., Zoëga, H., Furu, K., Bahmanyar, S., Martikainen, J. E., Kieler, 
H., & Pottegärd, A. (2016). Use of drugs for ADHD among adults – A 
multinational study among 15.8 million adults in the Nordic countries. 
European Journal of Pharmacology, 72, 1507-1514. 
https://doi.org/10.1007/s00228-016-2125-y 
Excluded The purpose explored use of pharmacotherapy for ADHD without the 
perceived efficacy of treatment. Consideration of use in introduction. 
Kiepek, N., Beagan, B., & Phelan, S. (2019). Substance use to enhance 
occupational performance and experience: A critical interpretive 
synthesis. Cadernos De Terapia Ocupacional Da UFSCar, 27(4), 843-857. 
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.4322/2526-8910.ctoAR1926 
Excluded Excluded for literature review as the information does not meet 
inclusion requirements. However, the article highlights the use of 
non-prescribed stimulant medications for cognitive enhancement 
(20% of university students) 
Klassen, L. J., Blackwood, C. M., Reaume, C. J., Schaffer, S., & Burns, J. G. 
(2018). A survey of adult referrals to specialist attention-deficit/hyperactivity 
disorder clinics in Canada. International Journal of General Medicine, 11, 1-
10. https://doi.org/10.2147/IJGM.S145269 
Excluded The article focuses on recommending family practitioners diagnose 
and manage care for adults with ADHD instead of referring to 
specialists. Referral should be reserved for complex case 
management 
Knouse, L. E., Teller, J., & Brooks, M. A. (2017). Meta-analysis of cognitive–
behavioral treatments for adult ADHD. Journal of Consulting and Clinical 
Psychology, 85(7), 737-750. http://doi.org/10.1037/ccp0000216 
Included Meta-analysis of CBT for adults with ADHD 
Lenzi, F., Cortese, S., Harris, J., & Masi, G.  (2018). Pharmacotherapy of 
emotional dysregulation in adults with ADHD: A systematic review and meta-
Included Systematic review and meta-analysis of effects of pharmacotherapy 









analysis. Neuroscience and Biobehavioral Reviews, 84, 359–367. 
https://doi.org/10.1016/j.neubiorev.2017.08.010 
include lack of differentiation between individuals with and without 
comorbid conditions and inability to analyze outcomes based on 
ADHD subtype 
Levin, F. R., Mariani, J. J., Specker, S., Mooney, M., Mahony, A., Brooks, D. 
J., Babb, D., Bai, Y., Eberly, L. E., Nunes, E. V., & Grabowski, J. (2015). 
Extended-release mixed amphetamine salts vs placebo for comorbid adult 
attention-deficit/hyperactivity disorder and cocaine use disorder: A 
randomized clinical trial. JAMA Psychiatry, 72(6), 593-602. 
https://doi.org/10.1001/jamapsychiatry.2015.41  
Excluded Did not meet inclusion criteria due to comorbid cocaine use 
Pettersson, R., Staffan, S., Söderström, K. E-, & Nilsson, K. W. (2017). 
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outpatient psychiatric care: A randomized trial. Journal of Attention Disorders, 
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Excluded Sample size was small with low power. The trial did not factor in 
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Ramsay, J. R. (2017). The relevance of cognitive distortions in the 
psychosocial treatment of adult ADHD. Professional Psychology: Research 
and Practice, 48(1), 62-69. http://doi.org /10.1037/pro000010 
Excluded Article does not meet inclusion requirements as the article addresses 
cognitive distortions and mindsets as a foundation for understanding 
treatment of adults with ADHD. While the information is useful to 
practice, it does not generate new information on the treatment of 
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Savulich, G., Thorp, E., Piercy, T., Peterson, K. A., Pickard, J. D., & Sahakian, 
B. J. (2019). Improvements in attention following cognitive training with the 
novel "Decoder" game on an iPad. Frontiers in Behavioral Neuroscience, 
13(2), 1-8. https://doi.org/10.3389/fnbeh.2019.00002 
Excluded The article used a sample of adults with no psychiatric diagnosis (past 
or current), including ADHD 
Smith, V. N-, Merwood, A., Hand, D., Brandling, J., Greenwood, R., Skinner, 
L., Law, S., Patel, V., & Rai, D. (2020). Non-pharmacological interventions 
for adult ADHD: A systematic review. Psychological Medicine, 50(4), 529–
541. https://doi.org/10.1017/S0033291720000069 
Included Systematic review of nonpharmacologic interventions for adults with 
ADHD 
Suzuki, C., Ikeda, Y., Tateno, A., Okubo, Y., Fukayama, H., & Suzuki, H. 
(2019). Acute atomoxetine selectively modulates encoding of reward value in 
ventral medial prefrontal cortex. J Nippon Medical School, 86(2), 98-107. 
https:// doi.org/10.1272/jnms.JNMS.2019_86-205 
Excluded Randomized, placebo controlled within-subjects cross-over trial 
Explores the effects of atomoxetine in the adult reward center of the 
brain, but not the adult with ADHD  
van Elst, L. T., Maier, S., Klöppel, S., Graf, E., Killius, C., Rump, M., 
Sobanski, E., Ebert, D., Berger, M., Warnke, A., Matthies, S., Perlov, E., & 
Philipsen, A. (2016). The effect of methylphenidate intake on brain structure in 
adults with ADHD in a placebo-controlled randomized trial. Journal of 
Psychiatry & Neuroscience, 41(6), 422-430. 
https://doi.org/10.1503/jpn.150320 
Excluded RCT on the effect of methylphenidate on brain structure which does 
not meet inclusion requirements. Consideration of use in introduction 
Verbeeck, W., Bekkering, G. E., Van den Noortgate, W., & Kramers, C. 
(2017).  Bupropion for attention deficit hyperactivity disorder (ADHD) in 
Included Systematic review assessing the efficacy of bupropion as therapy for 









adults. Cochrane Database Systematic Review, 10(10). 
https://doi.org/10.1002/14651858.CD009504.pub2 
Weyandt, L. L., Oster, D. R., Marraccini, M. E., Gudmundsdottir, B. G., 
Munro, B. A., Rathkey, E. S., & McCallum, A. (2016). Prescription stimulant 
medication misuse: Where are we and where do we go from 
here? Experimental and Clinical Psychopharmacology, 24(5), 400-414. 
http://doi.org/10.1037/pha0000093 
Excluded Article addresses prescription stimulant medication misuse that is not 
specific to adults with ADHD 
Yang, Z., Kelly, C., Castellanos, F. X., Leon, T., Milham, M. P., & Adler, L. 
A. (2016). Neural correlates of symptom improvement following stimulant 
treatment in adults with attention-Deficit/Hyperactivity disorder. Journal of 
Child and Adolescent Psychopharmacology, 26(6), 527-536. 
http://dx.doi.org.ezproxy.mnsu.edu/10.1089/cap.2015.0243 
Excluded The study examined the effects of amphetamines on the prefrontal 
cortex of the brain. Consideration of inclusion into the introduction  
Zimmermann, M. B., Diers, K., Strunz, L., Scherbaum, N., & Mette, C. 
(2019).  Listening to Mozart improves current mood in adult ADHD - A 
randomized controlled pilot study. Frontiers in Psychology, 10(1104).  
https://doi.org/10.3389/fpsyg.2019.01104 
Excluded The study focused on emotional lability associated with ADHD and 
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Alyagon U., Shahar H., Hadar A., 
Barnea-Ygael N., Lazarovits A., 
Shalev H., & Zangen A. (2020).  
Alleviation of ADHD symptoms 
by non-invasive right prefrontal 
stimulation is correlated with 
EEG activity. Neuroimage: 
























I  Conners’ Adult ADHD 
Rating Scale (CAARS); 













rTMS resulted in significant 
improvement of symptoms 
(p=0.00085) 
rTMS is a safe and effective treatment 
for ADHD 
Bachmann, K., Lam, A. P., & 
Philipsen, A. (2016). 
Mindfulness-based cognitive 
therapy and the adult ADHD 
brain: A neuropsychotherapeutic 
perspective. Frontiers in 
Psychiatry, 27(7), 117. 
https://doi.org/10.3389/fpsyt.2016
.00117 














Mindfulness meditation may 
reduce distractibility while 
cognitive therapy aids in 
improving coping and executive 
functioning skills. 
Mindfulness meditation as a 
neurobehavioral intervention may help 
adults with ADHD to improve self-
regulation.   
Baird, D., & Hoffman, A. (2019). 
Use of amphetamines for 
attention-deficit/hyperactivity 
disorder in adults. American 
Family Physician, 100(5), 278-


















I   Amphetamines provide a clinician 
rated 30% reduction in ADHD 
symptoms when compared with 
placebo (Strength of 
recommendation: B) 
While amphetamines may reduce 
clinician-rated symptoms in adults 
with ADHD, they were not found to 
improve global functioning or reduce 
accompanying symptoms of anxiety 
and depression.  Use of amphetamines 
are not without risk of adverse effects, 
including increased anxiety, depressed 
mood, nausea, vomiting, headache, 
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Boland, H., DiSalvo, M., Fried, 
R., Woodworth, K. Y., Wilens, 
T., Faraone, S. V., & Biederman, 
J. (2020). A literature review and 
meta-analysis on the effects of 
ADHD medications on functional 
outcomes. Journal of Psychiatric 
Research, 123, 21–30. 
https://doi.org/10.1016/j.jpsychire
s.2020.01.006 

























I   Pharmacotherapy is associated 
with a decreased risk of negative 
ADHD-associated functional 
outcomes. 
Early diagnosis and treatment of 
individuals with ADHD may improve 
functional outcomes. 
Cherkasova, F., French, L. R., 
Syer, C. A., Cousins, L., Galina, 
H., Kashani, Y. A-, & Hechtman, 
L. (2016). Efficacy of cognitive 
behavioral therapy with and 
without medication for adults 
with ADHD: A randomized 
clinical trial. Journal of Attention 























I Cognitive behavior 
therapy with and 
without medication; 
Conners’ Adult ADHD 
Diagnostic Interview for 
DSM-IV (CAARD-D); 
Barkley Current ADHD 
Symptoms Scale; 
Conners’ Adult ADHD 



























course of the 
study 
CBT, both with and without 
medication, resulted in significant 
improvements relative to baseline 
in ADHD symptoms and 
functional outcomes; CBT with 
medications was superior to CBT 
alone in reducing both self- and 
observed ADHD symptoms 
immediately while CBT alone 
improve more gradually. The 
CBT only group continued to 
improve after discontinuation of 
the CBT intervention, while this 
was not observed with the CBT 
plus medication group.   
CBT without medication is a viable 
option for those who cannot, or do not 
wish to, take stimulant medications.  
Corbisiero, S., Bitto, H., Newark, 
P., Mörstedt, B. A-, Elsässer, M., 
Kammermann, J. B-, Künne, S., 
Nyberg, E., Fallahpour, M. H-, & 
Stieglitz, R. D. (2018).  A 
comparison of cognitive-
behavioral therapy and 
To analyze the 
contribution of 
psychotherapy 
to the treatment 










I Methylphenidate; CBT 
Structured clinical 
interview for DSM-IV 
(SCID-I and SCID-II); 
Conners’ Adult ADHD 
Diagnostic Interview for 
DSM-IV (CAADID); 
Conners’ Adult ADHD 





every 4 days 




Individualized CBT program was 
not able to outperform standard 
clinical management (SCM).  
More information is needed to 
determine the effects of CBT therapy 
in addition to pharmacotherapy in 
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pharmacotherapy vs. 
pharmacotherapy alone in adults 
with attention-
deficit/hyperactivity disorder 
(ADHD) -- A randomized 




Conners’ ADHD Adult 
Rating Scale Self-
Report Short Version 
(CAARS-S:S); 
Conners’ Adult ADHD 















Life Scale (AAQol); 
General Perceived Self- 
Efficacy Scale (SWE); 
Rosenberg Self-Esteem 
Scale (RSES);  
Psychotherapy 
Motivation 
Questionnaire (FMP);  
Bern Post Session 
Report 
methylpheni









d to ADHD 
Cunill, R., Castells, X., Tobias, 
A., & Capellà, D. (2016). 
Efficacy, safety and variability in 
pharmacotherapy for adults with 
attention deficit hyperactivity 
disorder: A meta-analysis and 






































Pharmacological treatment was 
efficacious in reducing ADHD 
symptoms (p<0.00001) with 
stronger effect size with stimulant 
medications (Diff SMD=0.18, 
p=0.017); treatment with 
pharmacologic agents was 
associated with more frequent 
adverse effects (p=0.006).   
Efficacy of stimulant medication is 
greater than non-stimulant 
medications.  Must weight possible 
symptom relief with risks of adverse 
effects from treatment with stimulant 
medications. Providers must monitor 
for decreased efficacy of 






























































De Crescenzo, F., Cortese, S., 
Adamo, N., & Janiri, L. (2017). 
Pharmacological and non-
pharmacological treatment of 
To provide a 
reliable 







I Systematic reviews; 








(amphetamines) have higher 
efficacy than other forms of 
therapy, 
Risks-versus-benefits of stimulant 
medications should be considered 
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adults with ADHD: A meta-
review. Evidence - Based Mental 








Dittner, H., Hodsoll, J., Rimes, K. 
A., Russell, A. J., & Chalder, T. 
(2018). Cognitive-behavioural 
therapy for adult attention-deficit 
hyperactivity disorder: A proof of 
concept randomised controlled 
trial. Acta Psychiatrica 
































I Barkley Current 
Symptoms Scale; 




Significant improvement of 
symptoms as well as improved 
self-rated anxiety and depression, 
global distress, and patient 
satisfaction 
When added to treatment as usual, 
CBT had greater success in reducing 
ADHD symptoms and improving 
occupational and social functioning 
than treatment as usual (medication 
management) alone. 
Druedahl, L. C., & Sporrong S. 
K. (2018). Managing complexity: 
Exploring decision making on 
medication by young adults with 









VI Focus group 
Individual Interviews 
 Three major themes were revealed 
through analysis of date: 




2) Patient’s decision of 
whether or not to treat 
ADHD with medication 
3) Factors affecting 
patient’s decision on whether 
to take ADHD medication or 
not 
Understanding the factors influencing 
treatment choices helps prescribers 
empower patients 
Elliott, J., Johnston, A., Husereau, 
D., Kelly, S. E., Eagles, C., 
Charach, A., Hsieh, S., Bai, Z., 















High or unclear risk of bias in 
many studies; few differences 
between medications. 
Atomoxetine was associated with 
improved patient-reported clinical 
The choice between ADHD 
pharmacotherapies may depend on 
individual patient considerations; 
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Tsakonas, E., Chojecki, D., 
Mamdani, M., & Wells, G. A. 
(2020). Pharmacologic treatment 
of attention deficit hyperactivity 
disorder in adults: A systematic 
review and network meta-








response and quality of life 
compared with placebo. No 
significant difference in risk of 
serious adverse events or 
treatment discontinuation between 
ADHD pharmacotherapies and 
placebo, however the proportion 
of participants who withdrew due 
to adverse events was 
significantly higher among 
participants who received any 
ADHD pharmacotherapy.  
effects of individual 
pharmacotherapies 
Fuermaier, A. B. M., Tucha, L., 
Koerts, J., Weisbrod, M., Lange, 
K. W., Aschenbrenner, S., & 
Tucha, O. (2017). Effects of 
methylphenidate on memory 
functions of adults with ADHD. 
























II  MPH Nonmedicated adults with ADHD 
showed considerable impairments 
in memory function related to 
executive control; adults treated 
with MPH showed improved 
memory function compared to the 
nonmedicated group; healthy 
adults without ADHD showed the 
best memory function.  
Pharmacotherapeutics improve 
memory functions in adults with 
ADHD, however they are still 
impaired when compared with healthy 
controls. Nonpharmacologic therapy, 
in addition to pharmacotherapy, is 
likely necessary to improve memory 
functions. 
Geffen, J., & Forster, K. (2018). 
Treatment of adult ADHD: A 


















 I   Stimulant therapy is first-line for 
adults with ADHD.  Drug 
holidays are not necessary for 
adults. Non-stimulant therapy is 
second-line for adult ADHD and 
may be introduced as 1) 
monotherapy in patients not suited 
to stimulant therapy; 2) 
augmenting treatment in 
combination with stimulants; or 3) 
treatment for comorbid 
conditions. Combined 
pharmacotherapy and 
psychosocial therapy (CBT) is 
recommended.   
Practitioners should employ combined 
pharmacotherapy and psychosocial 
therapy for adults with ADHD. 
Goodman, D. W., Starr, H. L., 
Ma, Y. W., Rostain, A. L., 
Ascher, S., & Armstrong, R. B. 
(2017).  Randomized, 6-week, 









I Adult ADHD 
Investigator Symptom 





d dose of 36 
OROS MPH produced a 
significantly greater decrease in 
ADHD symptoms than placebo 
(P<.001).  Significantly more 
individuals achieved remission on 
Use of OROS methylphenidate may 
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placebo-controlled study of 
treatment for adult attention-
deficit/hyperactivity disorder: 
Individualized dosing of osmotic-
release oral system (OROS) 
methylphenidate with a goal of 
symptom remission. Journal of 





















Central Nervous System 









Inventory of Executive 
Function-Adult 
(BRIEF-A);  







Pittsburgh Sleep Quality 
Index (PSQI); 
Epworth Sleepiness 
Scale (ESS);  
InterSePT Scale for 
Suicidal Thinking 
(ISST-Plus) 
mg, 54 mg, 
or 72 mg/day 
until AISRS 





symptoms using OROS MPH than 
the placebo (P=.0008). OROS 
methylphenidate did not appear to 
negatively impact sleep compared 
to placebo, however self-reported 
feelings of insomnia.  
Goto, T, Hirata, Y., Takita, Y., 
Trzepacz, P. T., Allen, A. J., 
Song, D., Gau, S. S., Ichikawa, 
H., Takahashi, M. (2017). 
Efficacy and safety of 
atomoxetine hydrochloride in 
Asian adults with ADHD: A 10-
week randomized double-blind 
placebo-controlled Asian study. 
Journal of Attention Disorders, 
21(2), 100–109. 













I CAARS-Inv; quality of 
life (QoL); executive 
function (EF) 
Atomoxetine With atomoxetine there was a 
reduction in CAARS-Inv and 
improvements in QoL and EF 
Atomoxetine is an effective and 
tolerable treatment for adults with 

























Groß, V., Lücke, C., Graf, E., 
Lam, A. P., Matthies, S., Borel, 
P., Sobanski, E., Rösler, M., Retz, 
W., Jacob, C., Colla, M., Huss, 
M., Jans, T., Kis, B., Hamid, M. 
A-, van Elst, L. T., & Philipsen, 
A. (2019). Effectiveness of 
psychotherapy in adult ADHD: 
What do patients think? Results 
of the COMPAS study. Journal of 




















II  Patient-rated ADHD 
symptoms, CAARS-














































ADHD specific individual 
counseling post-treatment 
(P=<.0001) and at follow-up 
(P=.004).  
Group ADHD therapy may be an 
effective approach to symptom 
improvement  
Gutman, S. A., Balasubramanian, 
S., Herzog, M., Kim, E., 
Swirnow, H., Retig, Y., & Wolff, 











I Adult attention deficit 
hyperactivity disorder 
self-report scale;  




The intervention group revealed 
statistical improvement in 
perceived stress, ADHD 
symptoms, COPM, and 
satisfaction (P=.000) 
An intervention focusing on routine 
establishment, organization, time 
management, stress management, and 
sensory regulation in home and 




















Intervention Findings Implications 
 
tailored intervention for women 
with attention deficit 
hyperactivity disorder (ADHD) 
and ADHD symptoms: A 
randomized controlled study. 
American Journal of  

















US Canadian Occupational 
Performance Measure 
with ADHD, though more research is 
warranted. 
Janssen, L., Kan, C. C., 
Carpentier, P. J., Sizoo, B., 
Hepark, S., Schellekens, M. P. J., 
Rogier, A., Donders, T., 
Buitelaar, J. K., & Speckens, E. 
M. (2019). Mindfulness-based 
cognitive therapy v. treatment as 
usual in adults with ADHD: A 
multicentre, single-blind, 
randomised controlled trial. 






























MBCT + TAU revealed a 
significant reduction in clinician-
rated ADHD symptoms and the 
effect was maintained until 6-
month follow-up. No 
improvements were shown in the 
domain of executive function 
post-treatment, however there 
were improvements at the 6 
month follow-up.  
Mindfulness-based cognitive therapy 
may be an effective treatment option 
in addition to treatment as usual for 
adults with ADHD looking for 
enhanced symptom improvement.  
Knouse, L. E., Teller, J., & 
Brooks, M. A. (2017). Meta-
analysis of cognitive–behavioral 
treatments for adult 
ADHD. Journal of Consulting 


















CBT is associated with medium-
to-large effects on ADHD 
symptoms.  Effects of CBT were 
comparable for participants 
regardless of medication status or 
treatment format.  
CBT is a viable option for symptom 
reduction in adults with ADHD.  
Lenzi, F., Cortese, S., Harris, J., 
& Masi, G. (2018). 
Pharmacotherapy of emotional 






I Systematic review and 




MPH significantly more 
efficacious in reducing severity of 
emotional dysregulation 
Analysis reveals that medication was 
more efficacious than placebo at 




















Intervention Findings Implications 
 
dysregulation in adults with 
ADHD: A systematic review and 
meta-analysis. Neuroscience and 




























symptoms compared to placebo, 
SMD=0.34); atomoxetine showed 
a low effect size (SMD=0.24); 
lisdexamfetamine small-to-
medium effect size (SMD=0.34) 
increasing to moderate effect 
when removing cross-over studies 
(SMD=0.50) 
symptoms of emotional dysregulation. 
The effect is shown to be less than the 
reductions of core ADHD symptoms 
(impulsivity, distractibility, etc.).  It is 
not clear if mood stabilizing 
medications would be more effective 
at controlling symptoms of emotional 
dysregulation in adults with ADHD.  
Smith, V. N-, Merwood, A., 
Hand, D., Brandling, J., 
Greenwood, R., Skinner, L., Law, 
S., Patel, V., & Rai, D. (2020). 
Non-pharmacological 
interventions for adult ADHD: A 
systematic review. Psychological 














for those who 
have made the 
informed choice 




























Majority of individuals found 
symptom improvement with CBT 
treatment. 
CBT is a viable option for symptom 
reduction in adults with ADHD. 
Verbeeck, W., Bekkering, G. E., 
Van den Noortgate, W., & 
Kramers, C. (2017).  Bupropion 
for attention deficit hyperactivity 
disorder (ADHD) in adults. 
Cochrane Database Systematic 









US and Iran 
I  Bupropion 
use for adults 
with ADHD;  
placebo 
Low-quality evidence that 
bupropion decreased the severity 
of ADHD symptoms and 
moderately increased the 
proportion of participants 
achieving a significant clinical 
improvement in ADHD 
More research is needed to determine 
the efficacy of bupropion as a 

























symptoms. Tolerability of 
bupropion is similar to placebo.  
 
